Trials / Completed
CompletedNCT05529849
A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects
A Two-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Subcutaneous Doses of TCMCB07 on Healthy Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Endevica Bio · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TCMCB07 | Subcutaneous injection of TCMCB07 |
| DRUG | Placebo | Matching subcutaneous placebo |
Timeline
- Start date
- 2022-07-12
- Primary completion
- 2022-12-12
- Completion
- 2023-02-20
- First posted
- 2022-09-07
- Last updated
- 2024-02-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05529849. Inclusion in this directory is not an endorsement.